Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GamCovidVac (Altered Antigenic Profile) for COVID-19 Prevention
NCT06068569Phase 3
Key facts
- Status
- Unknown
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Viral Vector Vaccines
- Drugs
- Gam-COVID-Vac
- Conditions
- coronavirus disease 2019 (COVID-19)
01
Overview
Phase 3, randomised, open-label trial of Gam-COVID-Vac in coronavirus disease 2019 (COVID-19). Primary endpoints: Occurrence of adverse events at 28 days and Occurrence of serious adverse events. Status: unknown.
02
Design
1 arm- Study design
- RandomizedOpen-label
Healthy patients
GamCovidVac vector vaccine, two intramuscular injections
03
Who it enrols
Healthy adult volunteers over 18 years old, negative for COVID-19, HIV, Hepatitis B/C, syphilis, and without recent vaccinations, severe allergies, or significant medical history.
04
Endpoints
Primary
Occurrence of adverse events
Occurrence of serious adverse events
Beyond the preview
Go deeper on NCT06068569.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06068569.